Quality of Life Studies in Skin Cancer Treatment and Reconstruction

Andrew William Joseph

doi:10.1055/s-0040-1709130

Facial Plastic Surgery, Inhaltsverzeichnis

Facial Plast Surg 2020; 36(02): 194-199
DOI: 10.1055/s-0040-1709130

Original Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Quality of Life Studies in Skin Cancer Treatment and Reconstruction

Andrew William Joseph

¹Department of Otolaryngology—Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan

› Institutsangaben

Abstract

Health-related quality of life (HRQOL) is an important measure of patient experience before, during, and after treatment for skin cancers. Over the past 20 years, a variety of generic as well as disease-specific HRQOL instruments have been developed to assess clinical outcomes. Clinical trials have increasingly focused on using HRQOL instruments as outcome measures. Patients with both cutaneous melanoma and nonmelanotic skin cancers have been found to experience improvement in HRQOL following surgical treatment and reconstruction. Individual demographic variables may further predict experience within each of these groups. Increasing use of HRQOL instruments in future studies comparing skin cancer treatments will allow physicians to better understand and optimize patient experiences.

Keywords

facial reconstruction - health-related quality of life - quality of life - facial plastic surgery - head and neck reconstruction - skin cancer

Volltext

Referenzen

References
1 Chernyshov PV, Lallas A, Tomas-Aragones L. , et al. Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non-Melanoma Skin Cancer. J Eur Acad Dermatol Venereol 2019; 33 (05) 816-827
2 Wells GA, Russell AS, Haraoui B, Bissonnette R, Ware CF. Validity of quality of life measurement tools--from generic to disease-specific. J Rheumatol Suppl 2011; 88: 2-6
3 Waalboer-Spuij R, Nijsten TEC. A review on quality of life in keratinocyte carcinoma patients. G Ital Dermatol Venereol 2013; 148 (03) 249-254
4 Dobbs TD, Samarendra H, Hughes S, Hutchings HA, Whitaker I. Patient-reported outcome measures for facial skin cancer: a systematic review and evaluation of the quality of their measurement properties. Br J Dermatol 2019; 180 (05) 1018-1029
5 Aaronson NK, Ahmedzai S, Bergman B. , et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85 (05) 365-376
6 Groenvold M, Klee MC, Sprangers MA, Aaronson NK. Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epidemiol 1997; 50 (04) 441-450
7 Hjermstad MJ, Fossa SD, Bjordal K, Kaasa S. Test/retest study of the European Organization for research and treatment of cancer core quality-of-life questionnaire. J Clin Oncol 1995; 13 (05) 1249-1254
8 Sigurdardóttir V, Bolund C, Brandberg Y, Sullivan M. The impact of generalized malignant melanoma on quality of life evaluated by the EORTC questionnaire technique. Qual Life Res 1993; 2 (03) 193-203
9 Sigurdardóttir V, Bolund C, Sullivan M. Quality of life evaluation by the EORTC questionnaire technique in patients with generalized malignant melanoma on chemotherapy. Acta Oncol 1996; 35 (02) 149-158
10 Rhee JS, Matthews BA, Neuburg M, Logan BR, Burzynski M, Nattinger AB. Validation of a quality-of-life instrument for patients with nonmelanoma skin cancer. Arch Facial Plast Surg 2006; 8 (05) 314-318
11 Cormier JN, Ross MI, Gershenwald JE. , et al. Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer therapy-melanoma questionnaire. Cancer 2008; 112 (10) 2249-2257
12 Finlay AY, Khan GK. Dermatology life quality index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19 (03) 210-216
13 Basra MKA, Fenech R, Gatt RM, Salek MS, Finlay AY. The dermatology life quality index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159 (05) 997-1035
14 McHorney CA, Ware Jr JE, Lu JF, Sherbourne CD. The MOS 36-item Short-Form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32 (01) 40-66
15 EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 1990; 16 (03) 199-208
16 Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 2001; 5 (02) 105-110
17 Cano SJ, Browne JP, Lamping DL, Roberts AHN, McGrouther DA, Black NA. The patient outcomes of surgery-head/neck (POS-head/neck): a new patient-based outcome measure. J Plast Reconstr Aesthet Surg 2006; 59 (01) 65-73
18 Burdon-Jones D, Thomas P, Baker R. Quality of life issues in nonmetastatic skin cancer. Br J Dermatol 2010; 162 (01) 147-151
19 Lee EH, Klassen AF, Cano SJ, Nehal KS, Pusic AL. FACE-Q Skin Cancer Module for measuring patient-reported outcomes following facial skin cancer surgery. Br J Dermatol 2018; 179 (01) 88-94
20 Mori S, Blank NR, Connolly KL. , et al. Association of quality of life with surgical excision of early-stage melanoma of the head and neck. JAMA Dermatol 2019; 155 (01) 85-89
21 Bergenmar M, Månsson-Brahme E, Hansson J, Brandberg Y. Surgical resection margins do not influence health related quality of life or emotional distress in patients with cutaneous melanoma: results of a prospective randomised trial. Scand J Plast Reconstr Surg Hand Surg 2010; 44 (03) 146-155
22 Newton-Bishop JA, Nolan C, Turner F. , et al. A quality-of-life study in high-risk (thickness > = or 2 mm) cutaneous melanoma patients in a randomized trial of 1-cm versus 3-cm surgical excision margins. J Investig Dermatol Symp Proc 2004; 9 (02) 152-159
23 Petrella TM, Robert C, Richtig E. , et al. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. Eur J Cancer 2017; 86: 115-124
24 Schadendorf D, Amonkar MM, Stroyakovskiy D. , et al. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. Eur J Cancer 2015; 51 (07) 833-840
25 Grob JJ, Amonkar MM, Karaszewska B. , et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol 2015; 16 (13) 1389-1398
26 Coit DG, Thompson JA, Albertini MR, Barker C, Boland G. NCCN Clinical Practice Guidelines in Oncology Cutaneous Melanoma. December 2019. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf . Accessed January 12, 2020
27 Eigentler TK, Gutzmer R, Hauschild A. , et al; Dermatologic Cooperative Oncology Group (DeCOG). Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial. Ann Oncol 2016; 27 (08) 1625-1632
28 Mordoh J, Pampena MB, Aris M. , et al. Phase II study of adjuvant immunotherapy with the CSF-470 vaccine plus Bacillus Calmette-Guerin plus recombinant human granulocyte macrophage-colony stimulating factor vs medium-dose interferon alpha 2B in stages IIB, IIC, and III cutaneous melanoma patients: a single institution, randomized study. Front Immunol 2017; 8: 625
29 Long GV, Atkinson V, Ascierto PA. , et al. Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study. Ann Oncol 2016; 27 (10) 1940-1946
30 Young AM, Marsden J, Goodman A, Burton A, Dunn JA. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. Clin Oncol (R Coll Radiol) 2001; 13 (06) 458-465
31 Garbe C, Radny P, Linse R. , et al. Adjuvant low-dose interferon alpha2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol 2008; 19 (06) 1195-1201
32 Chren M-M, Sahay AP, Bertenthal DS, Sen S, Landefeld CS. Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol 2007; 127 (06) 1351-1357
33 Rhee JS, Matthews BA, Neuburg M, Logan BR, Burzynski M, Nattinger AB. The skin cancer index: clinical responsiveness and predictors of quality of life. Laryngoscope 2007; 117 (03) 399-405
34 Chen T, Bertenthal D, Sahay A, Sen S, Chren M-M. Predictors of skin-related quality of life after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. Arch Dermatol 2007; 143 (11) 1386-1392
35 Siegel JA, Chren M-M, Weinstock MA. ; Department of Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial Group. Correlates of skin-related quality of life (QoL) in those with multiple keratinocyte carcinomas (KCs): A cross-sectional study. J Am Acad Dermatol 2016; 75 (03) 639-642